COVID-19 prophylaxis with Doxycycline and Zinc in Health Care Workers: A prospective randomized double-blind clinical tria
Stambouli et al.,
COVID-19 prophylaxis with Doxycycline and Zinc in Health Care Workers: A prospective randomized double-blind..,
International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.06.016, NCT04584567
Prophylaxis RCT with 59 zinc + doxycycline, 56 doxycycline, and 57 placebo healthcare workers, showing lower symptomatic cases and significantly improved Ct values with the addition of zinc to doxycycline treatment. Doxycycline 100mg/day and zinc 15 mg/day.
risk of symptomatic case, 68.4% lower, RR 0.32, p = 0.36, treatment 1 of 59 (1.7%), control 3 of 56 (5.4%), NNT 27, zinc + doxycycline vs. doxycycline.
|
risk of case, 5.1% lower, RR 0.95, p = 1.00, treatment 5 of 59 (8.5%), control 5 of 56 (8.9%), NNT 220, zinc + doxycycline vs. doxycycline.
|
relative Ct values, 21.4% better, RR 0.79, p < 0.001, treatment mean 29.0 (±1.3) n=59, control mean 22.8 (±4.0) n=56, zinc + doxycycline vs. doxycycline.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Stambouli et al., 17 Jun 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Tunisia, peer-reviewed, 22 authors, study period 12 November, 2020 - 10 February, 2021, trial
NCT04584567 (history).
Contact:
nejlastam@gmail.com.
Abstract: Journal Pre-proof
COVID-19 prophylaxis with Doxycycline and Zinc in Health Care
Workers: A prospective randomized double-blind clinical trial
Nejla Stambouli , Adel Driss , Faten Gargouri , Khadija Bahrini ,
Bilel Arfaoui , Rim Abid , Karima Taamallah , Souha Hannachi ,
Sana Boughariou , Aicha Rebai , Imen Naas , Mohamed Ghanem ,
Hassib Ammar , Chiraz Aichaouia , Asma Harrathi ,
Mohamed Ali Yousfi , Riadh Battikh , Mohamed Ben Moussa ,
Rabie Razgallah , Mustapha Ferjani , Hédi Gharsallah , on behalf
of the of “OD-doxy-PNV-COVID-19 Trial”
PII:
DOI:
Reference:
S1201-9712(22)00349-6
https://doi.org/10.1016/j.ijid.2022.06.016
IJID 6251
To appear in:
International Journal of Infectious Diseases
Received date:
Revised date:
Accepted date:
2 March 2022
26 April 2022
13 June 2022
Please cite this article as: Nejla Stambouli , Adel Driss , Faten Gargouri , Khadija Bahrini ,
Bilel Arfaoui ,
Rim Abid ,
Karima Taamallah ,
Souha Hannachi ,
Sana Boughariou ,
Aicha Rebai ,
Imen Naas ,
Mohamed Ghanem ,
Hassib Ammar ,
Chiraz Aichaouia ,
Asma Harrathi , Mohamed Ali Yousfi , Riadh Battikh , Mohamed Ben Moussa , Rabie Razgallah ,
Mustapha Ferjani , Hédi Gharsallah , on behalf of the of “OD-doxy-PNV-COVID-19 Trial”,
COVID-19 prophylaxis with Doxycycline and Zinc in Health Care Workers: A prospective randomized double-blind clinical trial, International Journal of Infectious Diseases (2022), doi:
https://doi.org/10.1016/j.ijid.2022.06.016
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition
of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of
record. This version will undergo additional copyediting, typesetting and review before it is published
in its final form, but we are providing this version to give early visibility of the article. Please note that,
during the production process, errors may be discovered which could affect the content, and all legal
disclaimers that apply to the journal pertain.
© 2022 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
Research highlights
Using Doxycycline and Zinc as a potential treatment in SARS-COV-2 infection.
SARS-CoV-2 contamination appeared to be reduced after treatment.
COVID-19 infection risk was not associated with other comorbidities.
The combined treatments of Doxycycline and Zinc have minimal side effects.
1
COVID-19 prophylaxis with Doxycycline and Zinc in Health Care Workers:
A prospective randomized double-blind clinical trial
Nejla Stambouli1,11, Adel Driss2, Faten Gargouri1,§, Khadija Bahrini11,§, Bilel Arfaoui3,§,*, Rim Abid4,§,*, Karima
Taamallah8,*, Souha Hannachi4,§,*, Sana Boughariou5,*, Aicha Rebai5,*, Imen Naas5,*, Mohamed Ghanem6,*,
Hassib Ammar1, Chiraz Aichaouia7,*, Asma Harrathi1, Mohamed Ali Yousfi9,§, Riadh Battikh4,§,*, Mohamed
Ben Moussa10,§, Rabie Razgallah11, Mustapha Ferjani1,§,*, Hédi Gharsallah5,11,§,* on behalf of the of ―OD-doxyPNV-COVID-19 Trial‖†.
1
General Directorate of Military Health
2
Department of Physiology, Morehouse School of Medicine, Atlanta GA, USA.
3
Department of Internal Medicine
4
Department of Infectious Disease
5
Department of Intensive Care
6
Department of Gastroenterology
7
Department of Pneumology
8
Department of cardiology
9
Department of Pharmacy
10
Laboratory of..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit